Welcome to our dedicated page for Mirum Pharmaceuticals SEC filings (Ticker: MIRM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Mirum Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Mirum Pharmaceuticals's regulatory disclosures and financial reporting.
Mirum Pharmaceuticals Inc received an Amendment No. 1 Schedule 13G/A from The Vanguard Group describing an internal realignment under SEC Release No. 34-39538 (January 12, 1998). The filing states Vanguard and certain subsidiaries will report disaggregated holdings and that those subsidiaries pursue the same investment strategies. The filing reports amount beneficially owned: 0 and percent of class: 0% for Mirum common stock. The statement is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
Mirum Pharmaceuticals’ Chief Financial Officer Eric Bjerkholt exercised performance-based equity and sold shares mainly to cover taxes. He converted 13,334 performance restricted stock units into common stock at a conversion price of $0.0000 per unit. On the next trading day, 7,287 common shares were sold at an average price of $91.9779 per share to satisfy tax withholding obligations tied to this vesting. After these transactions, he directly held 49,788 shares of Mirum common stock.
Mirum Pharmaceuticals chief medical officer Joanne Quan exercised performance-based stock awards and sold shares mainly to cover taxes. On March 15, 2026, she exercised 13,334 performance restricted stock units, receiving the same number of Mirum common shares at a $0 exercise price, leaving 6,666 units outstanding. On March 16, 2026, she sold 7,287 shares of common stock in an open-market transaction at an average price of $91.9779 per share to satisfy tax withholding obligations tied to the vesting. After these transactions, Quan directly owned 18,864 Mirum common shares. The remaining performance units are scheduled to vest with two-thirds on March 15, 2026 and one-third on March 15, 2027, as described in the filing.
Mirum Pharmaceuticals director Saira Ramasastry exercised stock options and sold the resulting shares. On March 16, 2026, she exercised options for 2,000 shares of common stock at an exercise price of $23.51 per share, then sold 2,000 shares in an open‑market transaction at $90.76 per share.
The filing shows she no longer directly holds these 2,000 common shares after the sale. The transactions were carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted on September 18, 2025, indicating they were scheduled in advance rather than timed discretionarily.
Mirum Pharmaceuticals president and COO Peter Radovich reported a combination of equity award vesting and share sales. He exercised performance restricted stock units into 30,220 shares of common stock at a conversion price of $0.00 per share, increasing his direct holdings.
On the following day, he sold 16,515 common shares at an average price of $91.9779 per share, with a footnote stating the sale was to cover tax withholding obligations from the RSU vesting. After these transactions, he directly holds 40,272 common shares and continues to hold 11,500 performance restricted stock units scheduled to vest over future dates.
Mirum Pharmaceuticals, Inc. senior vice president and global controller Jolanda Howe exercised performance restricted stock units into 8,658 shares of common stock, each unit representing one share. On March 16, 2026, she sold 4,732 common shares at 91.9779 per share to cover tax withholding obligations related to this vesting, and held 8,429 shares afterward. Footnotes state the performance restricted stock units vest in stages over March 15, 2025–2027.
Mirum Pharmaceuticals CEO Christopher Peetz reported a mix of stock exercises and a tax-related sale. On March 15, 2026, he exercised performance restricted stock units covering 75,000 shares of common stock at a conversion price of $0.00, increasing his direct holdings.
On March 16, 2026, Peetz executed an open-market sale of 40,985 shares of common stock at an average price of $91.9779 per share. A footnote states these shares were sold to cover tax withholding obligations tied to the vesting of the performance restricted stock units, indicating a mechanistic, tax-driven transaction rather than a discretionary sale. After these transactions, he directly held 194,309 shares, with an additional 187,500 shares held indirectly by The Peetz Family Trust.
Mirum Pharmaceuticals submitted a Form 144 notice to sell 7,287 shares of Common Stock, tied to Restricted Stock Units vesting under a registered plan. The filing lists the proposed disposition by an issuer-related broker on 03/15/2026.
The filing also discloses two recent sales by Eric Bjerkholt: 1,421 shares sold on 01/22/2026 for $132,615.15 and 1,053 shares sold on 01/26/2026 for $101,290.18. The notice records the broker as Morgan Stanley Smith Barney LLC.
Joanne Quan reports proposed sale of 7,287 shares of Mirum Pharmaceuticals common stock. The Form 144 lists 7,287 shares tied to restricted stock units vesting under a registered plan and names Morgan Stanley Smith Barney LLC as broker, dated 03/16/2026. The filing also discloses prior dispositions of 6,911 shares on 01/20/2026 for $623,853.21 and 1,822 shares on 01/22/2026 for $170,038.51.
Mirum Pharmaceuticals notice of proposed sale: the filing reports a proposed sale of 16,515 shares of Common Stock, with an aggregate amount shown as $1,529,949.60, dated 03/16/2026. The filing states the securities are Restricted Stock Units vesting under a registered plan on 03/15/2026.
The filing also lists prior open-market sales by Peter Radovich of 2,382, 3,143 and 2,631 shares on 01/22/2026, 01/26/2026 and 02/02/2026, respectively, with corresponding aggregate values shown.